Intraday Economic News: U.S. Initial Jobless Claims Fall To 400,000 Aug 11

  • ID: 1857999
  • August 2011
  • Region: United States
  • Standard & Poors
1 of 2

U.S. initial jobless claims reportedly fell 1,000 to 400,000 in the week ended July 30. The reading was a little bit better than the 405,000 that consensus had expected. It comes after last week's reading was revised up to 401,000 from 398,000 claims. So the indicator still hasn't fallen to less than the 400,000 threshold for several months. Continuing claims rose 10,000 to 3.73 million from an upwardly revised 3.72 million the week before (was 3.703 million). The report came in about as expected and will likely be overlooked as markets brace for the government's payrolls report this Friday....

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Research Type: Commentary
Criteria articles describe the thought process and methodology Standard & Poor's analysts use in determining ratings. These commentary pieces discuss both the quantitative (economic and financial) and qualitative (business analysis and caliber of management) aspects of the analysis, as well as legal issues.

Note: Product cover images may vary from those shown
2 of 2
Note: Product cover images may vary from those shown


  • Quick Help: This Credit Rating Report will be emailed to you.


If you have a more general question about our products please try our



Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer, Inc.